Skip to content
    Real-World Studies

    Low HALP Score Linked to Worse Survival in Super-Elderly Gastric Cancer

    Inoue et alAnnals of Gastroenterological Surgery

    Low HALP Score Linked to Worse Survival in Super-Elderly Gastric Cancer
    A multicenter retrospective cohort study across 10 hospitals evaluated the prognostic significance and clinical robustness of preoperative hemoglobin, albumin, lymphocyte, and platelet (HALP) scores in 507 super-elderly patients (aged ≥ 80 years) undergoing curative gastrectomy for gastric cancer. The HALP score was calculated as hemoglobin × albumin × lymphocytes/platelets.
    Preoperative HALP scores ranged from 1.628 to 289.201, with a median of 50.795, and the optimal cutoff value for predicting overall survival was 42.382 based on receiver operating characteristic curve analysis. Multivariate analysis identified that low HALP scores (hazard ratio [HR], 2.23; 95% confidence interval [CI], 1.63–3.04; p < 0.001), male sex, high preoperative carcinoembryonic antigen levels, poor performance status, pT3/4, and pN(+) were independent risk factors for poor overall survival.
    The robustness of the prognostic significance of the HALP score was demonstrated using quartile, continuous variable, leave-one-center-out, and subgroup analyses. Additionally, a low HALP score was independently associated with worse cancer-specific survival (HR, 2.08) and other-cause mortality (HR, 2.39). The authors conclude that the HALP score appears to be a clinically useful and robust prognostic biomarker that may reflect both tumor- and host-related conditions, potentially contributing to prognostic stratification and clinical decision-making in super-elderly patients undergoing curative resection.

    Key Takeaways

    • In super-elderly patients undergoing curative gastrectomy for gastric cancer, a low preoperative HALP score was an independent risk factor for poor overall survival (HR, 2.23; 95% CI, 1.63–3.04; p < 0.001).
    • A low preoperative HALP score was independently associated with worse cancer-specific survival (HR, 2.08) and increased other-cause mortality (HR, 2.39).
    Read the original sourceAnnals of Gastroenterological Surgery